Recombinant quadrivalent influenza vaccine (RIV) induces robust cell-mediated and HA-specific B cell humoral immune responses among healthcare personnel
Vaccine · 2025
DOI: 10.1016/j.vaccine.2025.127361 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccine, 2025. Verfasst von Margarita Mishina und 26 weiteren Autor:innen. Beteiligte Einrichtung: Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: vvn6@cdc.gov. Hauptthemen laut MEDLINE: Influenza Vaccines, B-Lymphocytes, Health Personnel, Immunity, Humoral. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Intramural CDC HHS, NHLBI NIH HHS, National Center for Immunization and Respiratory Diseases.
Abstract (Originalsprache)
Egg-free influenza vaccines, specifically cell culture-based inactivated influenza vaccine (ccIIV) and recombinant influenza vaccine (RIV), represent a significant advancement over traditional egg-based inactivated influenza vaccines (IIV), particularly for populations with extensive vaccination histories. This comprehensive immunological study investigated the comparative efficacy of ccIIV, IIV, and RIV in healthcare personnel (HCP) with repeated vaccination histories, examining both cellular and humoral immune responses through multiple analytical approaches. Our investigation employed a multi-faceted analytical framework, combining serological assessments via hemagglutination inhibition (HI) and microneutralization (MN) assays with detailed cellular immune response analysis. We utilized advanced flow cytometry techniques with recombinant hemagglutinin (HA) probes to evaluate both circulating T follicular helper cells (cTfh) and HA-specific B cells, providing a comprehensive view of vaccine-induced immune responses. The results revealed RIV's superior immunogenicity profile, demonstrating significantly elevated levels of both cTfh and HA-specific B cells compared to ccIIV and IIV. RIV's enhanced performance was particularly evident in its response to influenza A components, with notably higher immunogenicity against both A(H3N2) and A(H1N1) strains. This superiority was reflected in elevated HI titers and markedly increased HA-specific B cell induction. While RIV also demonstrated enhanced HA-specific B cell responses against influenza B components compared to ccIIV, interestingly, HI titers remained comparable across all vaccine groups for these strains. These findings underscore the critical importance of comprehensive immune response evaluation in vaccine assessment. The disparity between cellular and serological responses, particularly for influenza HA-specific B cells, highlights that traditional serological measures alone may not fully capture the breadth and depth of vaccine-induced immunity. This study provides compelling evidence for the inclusion of cellular immunity assessments in vaccine evaluation protocols, offering crucial insights into vaccine immunogenicity that may be missed by conventional serological analysis alone.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: vvn6@cdc.gov.
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA; Oak Ridge Institute for Science and Education (ORISE), CDC Fellowship Program, Oak Ridge, TN, USA.
- Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA; Department of Anesthesiology, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY, US…
- Abt Associates, 2200 Century Pkwy NE Ste 950, Atlanta, GA, USA.
- Westat, 1600 Research Blvd, Rockville, MD, USA.
Förderung
- Intramural CDC HHS
- NHLBI NIH HHS
- National Center for Immunization and Respiratory Diseases
- National Heart Lung and Blood Institute
- Centers for Disease Control and Prevention
- U.S. Public Health Service
- Abt Global
Zitieren
APA
Mishina, M., Cao, W., Ende, Z., Sharma, S. S., Ray, S. D., Kumari, R., Kumar, A., Shanmugasundaram, U., Bohannon, C. D., Ranjan, P., Chang, J., Carney, P., Stevens, J., Levine, M. Z., Kim, S., Wesley, M., Ball, S., Pando, M. J., Dobin, S., …, & Sambhara, S. (2025). Recombinant quadrivalent influenza vaccine (RIV) induces robust cell-mediated and HA-specific B cell humoral immune responses among healthcare personnel. Vaccine. https://doi.org/10.1016/j.vaccine.2025.127361
Vancouver
Mishina M, Cao W, Ende Z, Sharma SS, Ray SD, Kumari R, et al. Recombinant quadrivalent influenza vaccine (RIV) induces robust cell-mediated and HA-specific B cell humoral immune responses among healthcare personnel. Vaccine. 2025. doi:10.1016/j.vaccine.2025.127361
BibTeX
@article{Mishina2025,
author = {Mishina, Margarita and Cao, Weiping and Ende, Zachary and Sharma, Suresh S and Ray, Sean D and Kumari, Rashmi and Kumar, Amrita and Shanmugasundaram, Uma and Bohannon, Caitlin D and Ranjan, Priya and Chang, Jessie and Carney, Paul and Stevens, James and Levine, Min Z and Kim, Sara and Wesley, Meredith and Ball, Sarah and Pando, Marcelo Jorge and Dobin, Sheila and Knight, Paul R and Varadarajan, Raghavan and Thompson, Mark and Dawood, Fatimah S and Naleway, Allison L and Gaglani, Manjusha and Gangappa, Shivaprakash and Sambhara, Suryaprakash},
title = {Recombinant quadrivalent influenza vaccine (RIV) induces robust cell-mediated and HA-specific B cell humoral immune responses among healthcare personnel},
journal = {Vaccine},
year = {2025},
doi = {10.1016/j.vaccine.2025.127361}
}
EUVIMED